Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer

Journal of Materials Science: Materials in Medicine

Volumn 21, Issue 9, 2010, Pages 2683-2690

  Forster, Richard E J ^a,b   Small, Sharon A ^a   Tang, Yiqing ^a   Heaysman, Clare L ^a   Lloyd, Andrew W ^b   MacFarlane, Wendy ^b   Phillips, Gary J ^b   Antonijevic, Milan D ^c   Lewis, Andrew L ^a  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

^c UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPRESSIBILITY MODULUS; CYTOTOXIC; DOXORUBICIN; DRUG LOADING; DRUG LOADING CAPACITY; EMBOLISATION; HYDROGEL MATRIX; IN-VITRO; IRINOTECAN; LIVER CANCERS; MAXIMUM LOADING; PANCREATIC ADENOCARCINOMA; PANCREATIC CANCERS; STATIC LOADING; SUSTAINED-RELEASE; TOPOISOMERASE I; TOPOTECAN;

DRUG DELIVERY; ENZYME INHIBITION; HYDRATES; HYDROGELS; LOADING; MECHANICAL PROPERTIES;

DRUG DOSAGE;

IRINOTECAN; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG RELEASE; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO SELECTION; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; HUMANS; PANCREATIC NEOPLASMS; TOPOTECAN;

EID: 77956933852     PISSN: 09574530     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10856-010-4107-4     Document Type: Article

References (23)

1. GL Beretta P Perego F Zunino 2008 Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors Expert Opin Ther Targets 12 10 1243 1256 1:CAS:528:DC%2BD1cXhtFSmsrjF 10.1517/14728222.12.10.1243 18781823
2. M Potmesil 1994 Camptothecins: from bench research to hospital wards Cancer Res 54 6 1431 1439 1:CAS:528:DyaK2cXitVOktbo%3D 8137244
3. K Malagari 2008 Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead Expert Rev Anticancer Ther 8 10 1643 1650 1:CAS:528:DC%2BD1cXht1yjtb3N 10.1586/14737140.8.10.1643 18925855
4. J Kettenbach A Stadler IV Katzler R Schernthaner M Blum J Lammer T Rand 2008 Drug-loaded microspheres for the treatment of liver cancer: review of current results Cardiovasc Intervent Radiol 31 3 468 476 10.1007/s00270-007- 9280-6 18228095
5. RT Poon WK Tso RW Pang KK Ng R Woo KS Tai ST Fan 2007 A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead Clin Gastroenterol Hepatol 5 9 1100 1108 1:CAS:528: DC%2BD2sXhtFKrt7%2FE 10.1016/j.cgh.2007.04.021 17627902
6. T de Baere F Deschamps C Teriitheau P Rao K Conengrapht M Schlumberger S Leboulleux E Baudin L Hechellhammer 2008 Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads preliminary results J Vasc Interven Radiol 19 6 855 861 10.1016/j.jvir.2008.01.030
7. C Aliberti M Tilli G Benea G Fiorentini 2006 Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results Anticancer Res 26 5 3793 3795 1:STN:280:DC%2BD28nlvF2mtw%3D%3D 17094403
8. G Fiorentini C Aliberti G Turrisi A Del Conte S Rossi G Benea P Giovanis 2007 Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study In Vivo 21 6 1085 1091 1:CAS:528:DC%2BD1cXkvVantQ%3D%3D 18210761
9. M Keese L Gasimova K Schwenke V Yagublu E Shang R Faissner A Lewis S Samel M Löhr 2009 Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer Int J Cancer 124 11 2701 2708 1:CAS:528:DC%2BD1MXltlegtbk%3D 10.1002/ijc.24211 19165866
10. S Baltes I Freund AL Lewis I Nolte T Brinker 2010 Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model J Mater Sci: Mater Med 21 4 1393 1402 1:CAS:528:DC%2BC3cXktFyqurw%3D 10.1007/s10856-009-3803-4
11. AL Lewis 2009 DC Bead: a major development in the toolbox for the interventional oncologist Expert Rev Med Devices 6 4 389 400 1:CAS:528:DC%2BD1MXotleit70%3D 10.1586/erd.09.20 19572794
12. MV Gonzalez Y Tang GJ Phillips AW Lloyd B Hall PW Stratford AL Lewis 2008 Doxorubicin eluting beads-2: methods for evaluating drug elution and in vitro: in vivo correlation J Mater Sci: Mater Med 19 2 767 775 1:CAS:528: DC%2BD1cXhs1Wrt70%3D 10.1007/s10856-006-0040-y (Pubitemid 351244006)
13. AL Lewis MV Gonzalez SW Leppard JE Brown PW Stratford GJ Phillips AW Lloyd 2007 Doxorubicin eluting beads-1: effects of drug loading on bead characteristics and drug distribution J Mater Sci: Mater Med 18 9 1691 1699 1:CAS:528:DC%2BD2sXos1Cgu7o%3D 10.1007/s10856-007-3068-8 (Pubitemid 47224923)
14. Y Tang PR Czuczman ST Chung AL Lewis 2008 Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases J Control Release 127 1 70 78 1:CAS:528: DC%2BD1cXjt12qs7w%3D 10.1016/j.jconrel.2007.12.012 18237814
15. Chu E, Sartorelli AC. Cancer chemotherapy. In: Katzung BG, editor. Basic & clinical pharmacology. McGraw-Hill Professional, 2007; 2007.
16. T Lesimple MB Hassel D Gedouin E Seigneuret B Carsin A Hamlat L Riffaud H Simon JP Malhaire Y Guegan 2003 Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma J Neurooncol 65 2 141 148 10.1023/B:NEON.0000003647.66788.3b 14686734 (Pubitemid 37521313)
17. RR Taylor Y Tang MV Gonzalez PW Stratford AL Lewis 2007 Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties Eur J Pharm Sci 30 1 7 14 1:CAS:528:DC%2BD28XhtlalsbnP 10.1016/j.ejps.2006.09.002 17030118 (Pubitemid 44908921)
18. SA Strel'tsov SL Grokhovskii IA Kudelina VA Oleinikov AL Zhuze 2001 [Interaction of topotecan-a DNA topoisomerase inhibitor-with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution] Mol Biol (Mosk) 35 3 432 441
19. S O'Reilly RC Donehower EK Rowinsky S Ord LB Grochow 1996 A phase II trial of topotecan in patients with previously untreated pancreatic cancer Anticancer Drugs 7 4 410 414 10.1097/00001813-199606000-00006 8826609 (Pubitemid 26249194)
20. JP Stevenson RM Scher R Kosierowski SC Fox M Simmonds KS Yao F Green C Broom SZ Fields JB Krebs, et al. 1998 Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas Eur J Cancer 34 9 1358 1362 1:CAS:528:DyaK1cXlvVChtro%3D 10.1016/S0959-8049(98)00053-7 9849417 (Pubitemid 28370926)
21. Y Saito M Yasunaga J Kuroda Y Koga Y Matsumura 2008 Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor Cancer Sci 99 6 1258 1264 1:CAS:528:DC%2BD1cXnsVOrsb0%3D 10.1111/j.1349-7006.2008.00806.x 18429960 (Pubitemid 351676640)
22. SH Akbas M Timur T Ozben 2005 The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells J Surg Res 125 1 49 55 1:CAS:528:DC%2BD2MXjt1Wjt7c%3D 10.1016/j.jss.2004.11.011 15836850 (Pubitemid 40523775)
23. J Pollina RJ Plunkett MJ Ciesielski A Lis TA Barone SJ Greenberg RA Fenstermaker 1998 Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model J Neurooncol 39 3 217 225 1:STN:280:DyaK1M%2FjvVGnug%3D%3D 10.1023/A:1005954121521 9821107 (Pubitemid 28482557)